Respiratory Tract Infection
- Respiratory infections cause more doctor visits and absences from school and work than any other illness.1
- Most people experience an average of 2 respiratory infections each year; these infections can lead to severe disease in high risk populations, which include young children, the elderly, and anyone with weakened or compromised immune systems.2
- Only 16% of positive results are Influenza A3, underscoring need for more rapid, accurate and comprehensive testing platforms.
- While culture-based testing historically is the Gold Standard, RT-PCR RPP tests for multiple pathogens from a single specimen and is more sensitive and specific.
Request Test Kits
Please indicate the quantity of test kits you would like to receive, then proceed to the next page to confirm your shipping and contact information. Please note: complimentary sample kits are only available to licensed medical professionals.
Polymerase Chain Reaction (PCR) Respiratory Pathogen Panel RPP Test
- Rapid - Improves speed and accuracy of respiratory pathogen detection in a matter of hours versus days with culture-based testing
- Accurate - Identication of 9 bacterial pathogens and 26 Viral pathogens from a single specimen
- Comprehensive - PCR allows for earlier intervention, improved patient outcomes via optimized therapy with our Respiratory Pathogen Panel
- Our Respiratory Pathogen Panel (RPP) tests for common pathogens which may be bacterial or viral. Real Time-Polymerase Chain Reaction testing (RT-PCR) quickly aides in pathogen identication which can discourage unnecessary antibiotic usage and optimized patient care
Culture Based Testing
- Turnaround time for conventional virus detection methods ranges from approximately 2 to 3 hours for Direct Fluorescent Antibody test (DFA) to 2 to 3 days for Culture Augmented-Direct Fluorescent Antibiody test (CA-DFA) and up to 1 to 2 weeks for virus isolation. The m-RT-PCR-ELAHA assay, on the other hand, had a turnaround time for results that was less than 5 hours4
- Many clinically relevant viruses are difficult to grow in culture (such as rhinovirus and coronavirus) and may produce variable results
- Rapid laboratory diagnosis of HRSV (Human Respiratory Syncytial Virus) infection in children and infants can be critical for effective patient management by focusing appropriate drug treatment, reducing unnecessary use of antibiotics, and preventing nosocomial spread
Our Respiratory Pathogen Panel
9 Bacterial Pathogens Detected
| Target Organism | Assay name |
| Bordetella bronchiseptical parapertussis / pertussis | Bordetella |
| Bordetella pertussis | B. pertussis |
| Chlamydophila pneumoniae | C. pneumoniae |
| Haemophilus inuenzae | H. inuenzae |
| Klebsiella pneumoniae | K. pneumoniae |
| Legionella pneumophila | L. pneumophila |
| Mycoplasma pneumoniae | M. pneumoniae |
| Staphylococcus aureus | S. aureus |
| Streptococcus pneumoniae | S. pneumoniae |
26 Viral Pathogens Detected
| Target Organism | Assay name |
| Adenovirus | AdV_1of2 |
| Adenovirus | AdV_1of2 |
| Human Bocavirus | HBoV |
| Human Coronavirus 229E | CoV_229E |
| Human Coronavirus HKU1 | CoV_HKU1 |
| Human Coronavirus NL63 | CoV_NL63 |
| Human Coronavirus OC43 | CoV_OC43 |
| Human Enterovirus [pan assay] | EV_pan |
| Human Enterovirus D68 | EV_D68 |
| Human Metapneumovirus (hMPV) | hMPV |
| Human Parainuenza virus 1 | hPIV1 |
| Human Parainuenza virus 2 | hPIV2 |
| Human Parainuenza virus 3 | hPIV3 |
| Human Parainuenza virus 4 | hPIV4 |
| Human Respiratory Syncytial Virus A (RSVA) | RSVA |
| Human Respiratory Syncytial Virus B (RSVB) | RSVB |
| Human Rhinovirus 1/2 | RV_1of2 |
| Human Rhinovirus 2/2 | RV_2of2 |
| Human herpesvirus 3 [HHV3 – Varicella zoster Virus] | HHV3 |
| Human herpesvirus 4 [HHV4 – Epstein-Barr Virus] | HHV4 |
| Human herpesvirus 5 [HHV5 – Cytomegalovirus] | HHV5 |
| Human herpesvirus 6 [HHV6] | HHV6 |
| Inuenza A | Flu_A_pan |
| Inuenza A/H1-2009 | FLu_A_H1 |
| Inuenza A/H3 | FLu_A_H3 |
| Inuenza B | FLu_B_pan |
High Risk Groups
- Children younger than 5 - especially children less than 2 years old
- Adults 65 years of age and older
- Pregnant women
- Critically ill patients - especially immunocompromised, (i.e. cancer and transplant patients)
Clinical Benefits
- Rapid detection of multiple pathogens from a single specimen, often in hours.
- Accurate and Comprehensive Results
- Better Patient Outcomes
- Antibiotic Stewardship
Sample Report
Request Test Kits
Please indicate the quantity of test kits you would like to receive, then proceed to the next page to confirm your shipping and contact information. Please note: complimentary sample kits are only available to licensed medical professionals.
1) Johns Hopkins Medicine Health Library. http://www.hopkinsmedicine.org/healthlibrary/conditions/pediatrics/upper_respiratory_infection_uri_or_common_cold_90,P02966 (accessed February 2016)
2) American College of Physicians: A Guide to Managing Respiratory Infections. Breathe Easy. 2008
3) Schreckenberger, P. and McAdam, A. (2015). Point-Counterpoint: Large Multiplex PCR Panels Should Be First-Line Tests for Detection of Respiratory and Intestinal Pathogens. J Clin Microbiol. 53(10):3110-5. doi: 10.1128/JCM.00382-15
4) Journal of Molecular Diagnostics, Vol. 6, No. 2, May 2004 Copyright © American Society for Investigative Pathology and the Association for Molecular Pathology A Sensitive, Specific, and Cost-Effective Multiplex Reverse Transcriptase-PCR Assay for the Detection of Seven Common Respiratory Viruses in Respiratory Samples Melanie W. Syrmis,*†‡ David M. Whiley,*† Marion Thomas,‡ Ian M. Mackay,*†‡ Jeanette Williamson,§ David J. Siebert,§ Michael D. Nissen,‡ and Theo P. Sloots*†‡§
5) Point: is the era of viral culture over in the clinical microbiology laboratory Hodinka RLJ Clin Microbiol. 2013 Jan; 51(1):2-4.
6) J Clin Microbiol. 2002 Dec; 40(12): 4418–4422. doi: 10.1128/JCM.40.12.4418-4422.2002PMCID: PMC154614PMID: 12454129
Detection of Human Respiratory Syncytial Virus in Respiratory Samples by LightCycler Reverse Transcriptase PCRDavid M. Whiley, 1,2 Melanie W. Syrmis,1,2,3 Ian M. Mackay,1,2,3 and Theo P. Sloots1,2,3,4,*
